CClinicalTrials.gg
RecruitingNCT07118332Updated Aug 3, 2026

Psilocybin as a Treatment for Chronic Pain in Smokers

An Early Phase 1 interventional study of Psilocybin (drug) in Smokers With Chronic Pain, sponsored by Yale University. Recruiting at 2 sites in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by Yale University · Early Phase 1, Interventional, and Health services research

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to understand whether psilocybin therapy is safe and well tolerated in improving chronic pain and increasing motivation to quit smoking for people who have chronic pain and smoke cigarettes. Psilocybin is a psychedelic drug and the active ingredient in "magic mushrooms." Psilocybin is currently being studied in clinical trials but has no current medical use in the United States. Some studies have shown that a dose of psilocybin can help people quit smoking. Other studies have shown that a dose of psilocybin may improve certain chronic pain conditions, such as migraine headaches. We believe that it may also be helpful for people who smoke and have chronic pain, but this has not been tested yet.

Read the detailed description

This will be an open-label pilot study examining the feasibility and potential efficacy of psilocybin in individuals who smoke and have chronic pain. Following the screening visit, the potential participants will have 1) an adaptation/preparation session, 2) a treatment session, and 3) two post-treatment follow-up sessions: 1 and 4 weeks after the treatment session. During study participation, participants will also complete surveys 4 times per day on a mobile device for 5 weeks (1 week before the treatment session and 4 weeks post-treatment session).

General Procedures: Potential participants will undergo extensive medical and psychiatric screening to minimize the risk of study participation. Psilocybin will be administered as a 25 mg oral dose under close medical and psychiatric monitoring.

For the 24 hours before the treatment session, subjects will be asked to abstain from consuming alcoholic beverages and any illicit drugs, verified by urine drug screening and breathalyzer. Non-compliant subjects will be rescheduled or discharged from the study if they are repeatedly non-compliant. Subjects will be instructed to drink their typical number of caffeinated beverages and smoke cigarettes as usual to minimize caffeine and tobacco withdrawal, which could confound the study measures. Subjects will be instructed not to eat for 4 hours before the treatment sessions because a light snack will be provided before the beginning of the session, and lunch will be provided at the end.

02

Conditions studied

  • Smokers With Chronic Pain

Browse trials for

Keywords

  • cigarettes
  • pain
03

In context

Pain

2,219 studies on the registry are indexed under Pain; 917 are open to participants now.

This study's planned enrollment of 10 is below the median of 70 across 1,904 interventional studies indexed under Pain.

Browse Pain studies →

Lead sponsor

Yale University is the lead sponsor of 1,724 studies on the registry; 298 are open to participants now.

Of its 210 completed or terminated interventional studies of FDA-regulated products, 126 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Veterans aged 21 to 65 years, who have been smoking tobacco cigarettes daily cigarettes for at least a year (confirmed with urine cotinine strips indicating smoking status (28)
  • not seeking treatment at the time of the study for tobacco use.
  • endorsement of bothersome or high-impact chronic non-cancer pain per the Graded Pain Scale - Revised (29);
  • in good health as verified by medical history, screening examination, and screening laboratory tests; and
  • body mass index (BMI) between 18 to 35 because there is limited information on the safety of psilocybin in individuals outside this range.
  • for women, not pregnant as determined by pregnancy screening, nor breastfeeding, and using acceptable birth control methods (e.g., oral contraceptives).

Exclusion criteria

Exclusion Criteria:

  • History of major medical disorders (e.g., diabetes, epilepsy, kidney or liver diseases, heart rhythm problems, heart failure, hypertension with BP greater than 140/90mmHg, history of cerebrovascular problems, severe asthma, etc.).
  • lifetime history of schizophrenia, bipolar disorder, dissociative disorders, or borderline personality disorder, current major depressive episode, or PTSD.
  • first- or second-degree relatives with a history of bipolar disorder or schizophrenia.
  • suicide attempt or ideation in the past year.
  • regular use of certain psychotropic medications (antidepressants, antipsychotics, mood stabilizers or anxiolytics) that are deemed to have the potential for adverse effects or drug reactions with psilocybin including SSRIs and MAO inhibitors.
  • current untreated moderate or severe substance use disorder for any other recreational or prescription drugs other than nicotine.
  • known sensitivity or intolerability to psilocybin.
05

Study design

Phase
Early Phase 1
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Psilocybin 25mg

    Drug: Psilocybin (drug)

Interventions

  • DrugPsilocybin (drug)

    25mg of Psilocybin will be given to all subject

06

What researchers measure

Primary outcomes

  1. SAFTEE scale

    The SAFTEE will be administered before and after each session to monitor adverse events from the study medications. The SAFTEE has been used in many pharmacotherapy trials (52) and includes possible side effects of study medications.

    Time frame: Day 1 and Day 7

07

Study locations

1 of 2 sites recruiting
  • Department of Veterans Affairs
    West Haven, Connecticut 06516, United States
    • Mehmet Sofuoglu, M.D., Ph.D. · Principal investigator
    Not yet recruiting
  • Department of Veterans Affairs
    West Haven, Connecticut 06516, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07118332
Lead sponsor
Yale University
Responsible party
Mehmet Sofuoglu (Professor of Psychiatry • MEDPSY Psych Divisions- SATU, Yale University) — Principal investigator
First posted
Aug 12, 2025
Start date
Jul 6, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Mehmet Sofuoglu, M.D., Ph.D.
Contact
Mehmet.Sofuoglu@va.gov
203-932-5711

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion